Suppr超能文献

胃肠道癌肝转移及耐药的细胞和分子机制。

Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance.

机构信息

Department of Pain, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China.

Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Key Laboratory of Molecular Pathology and Epidemiology of Gastric Cancer in the Universities of Liaoning Province, Shenyang, Liaoning 110001, China.

出版信息

Drug Resist Updat. 2024 Nov;77:101125. doi: 10.1016/j.drup.2024.101125. Epub 2024 Aug 6.

Abstract

Distant metastases and drug resistance account for poor survival of patients with gastrointestinal (GI) malignancies such as gastric cancer, pancreatic cancer, and colorectal cancer. GI cancers most commonly metastasize to the liver, which provides a unique immunosuppressive tumour microenvironment to support the development of a premetastatic niche for tumor cell colonization and metastatic outgrowth. Metastatic tumors often exhibit greater resistance to drugs than primary tumors, posing extra challenges in treatment. The liver metastases and drug resistance of GI cancers are regulated by complex, intertwined, and tumor-dependent cellular and molecular mechanisms that influence tumor cell behavior (e.g. epithelial-to-mesenchymal transition, or EMT), tumor microenvironment (TME) (e.g. the extracellular matrix, cancer-associated fibroblasts, and tumor-infiltrating immune cells), tumor cell-TME interactions (e.g. through cytokines and exosomes), liver microenvironment (e.g. hepatic stellate cells and macrophages), and the route and mechanism of tumor cell dissemination (e.g. circulating tumor cells). This review provides an overview of recent advances in the research on cellular and molecular mechanisms that regulate liver metastases and drug resistance of GI cancers. We also discuss recent advances in the development of mechanism-based therapy for these GI cancers. Targeting these cellular and molecular mechanisms, either alone or in combination, may potentially provide novel approaches to treat metastatic GI malignancies.

摘要

胃肠道(GI)恶性肿瘤如胃癌、胰腺癌和结直肠癌患者的生存预后较差,主要与远处转移和耐药相关。GI 肿瘤最常转移到肝脏,肝脏为肿瘤细胞定植和转移生长提供了独特的免疫抑制肿瘤微环境。转移性肿瘤往往比原发性肿瘤对药物具有更强的耐药性,这给治疗带来了额外的挑战。GI 癌症的肝转移和耐药性受复杂、相互交织和依赖肿瘤的细胞和分子机制调控,这些机制影响肿瘤细胞行为(如上皮-间充质转化,或 EMT)、肿瘤微环境(TME)(如细胞外基质、癌相关成纤维细胞和肿瘤浸润免疫细胞)、肿瘤细胞-TME 相互作用(如通过细胞因子和外泌体)、肝微环境(如肝星状细胞和巨噬细胞)以及肿瘤细胞播散的途径和机制(如循环肿瘤细胞)。本文综述了调控 GI 癌症肝转移和耐药性的细胞和分子机制的研究进展,并讨论了针对这些 GI 癌症的基于机制的治疗方法的最新进展。针对这些细胞和分子机制,无论是单独靶向还是联合靶向,都可能为治疗转移性 GI 恶性肿瘤提供新的方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验